STAR Protocols, Journal Year: 2025, Volume and Issue: 6(2), P. 103742 - 103742
Published: April 7, 2025
Language: Английский
npj Precision Oncology, Journal Year: 2024, Volume and Issue: 8(1)
Published: July 18, 2024
Abstract Immunotherapy has largely failed in ovarian carcinoma (OC), likely due to that the vast tumor heterogeneity and variation immune response have hampered clinical trial outcomes. Tumor-immune microenvironment (TIME) profiling may aid stratification of OC tumors for guiding treatment selection. Here, we used Digital Spatial Profiling combined with image analysis characterize regions spatially distinct TIME phenotypes assess whether infiltration pattern can predict presence immuno-oncology targets. Tumors diffuse increased tumor-immune spatial interactions had higher IDO1, PD-L1, PD-1 Tim-3, while focal niches more CD163 macrophages a preliminary worse outcome. Immune exclusion was associated Tregs Fibronectin. High-grade serous showed an overall stronger multiple targetable checkpoints. Low-grade high expression STING, endometrioid CTLA-4. Mucinous clear cell were dominated by clusters immune-excluded regions, mucinous displaying T-cell rich niches.
Language: Английский
Citations
4
Advanced Materials, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 18, 2024
Photoagents with ultra-high near-infrared II (NIR-II) light energy conversion efficiency hold great promise in tumor phototherapy due to their ability penetrate deeper tissues and minimize damage surrounding healthy cells. However, the development of NIR-II photoagents remain challenging. In this study, an all-fused-ring quinoidal acceptor-donor-acceptor (A-D-A) molecule, SKCN, a BTP core is synthesized, nanoparticles named FA-SNPs are prepared. The unique structure enhances π-electron delocalization bond length uniformity, significantly reducing bandgap resulting strong absorption, high molar extinction coefficient, photothermal 75.14%. Enhanced molecular rigidity also facilitates efficient transfer oxygen, boosting reactive oxygen species generation. By incorporating immunomodulator R848, FA-SRNPs further developed, effectively modulating immune microenvironment by Tregs M-MDSCs infiltration, promoting dendritic cell maturation, M1 macrophage polarization, activating CD8+ T cells NK Comprehensive studies using orthotopic ovarian cancer models demonstrated targeting, photoacoustic imaging capabilities, significant suppression metastasis inhibition, showing excellent therapeutic efficacy breast model. This study provides evidence for potential application A-D-A molecules photoimmunotherapy.
Language: Английский
Citations
4
Genes & Diseases, Journal Year: 2025, Volume and Issue: unknown, P. 101519 - 101519
Published: Jan. 1, 2025
Language: Английский
Citations
0
Biomedicines, Journal Year: 2025, Volume and Issue: 13(1), P. 168 - 168
Published: Jan. 12, 2025
Background/Objectives: It remains challenging to treat recurrent ovarian cancer effectively as traditional interventions like chemotherapy and surgery have limited long-term efficacy, highlighting an urgent need for innovative approaches. Immunotherapy offers potential advantages in modulating the immune response against tumor cells has emerged a promising strategy management. This review discusses various immunotherapy modalities, including active passive strategies, cancer. Methods: We systematically reviewed recent advances cancer, efficacy mechanisms of single dual checkpoint inhibitors, inhibitor combinations with or radiotherapy, anti-angiogenic agents, PARP antibody–drug conjugates (ADC), vaccines, adoptive cell therapies (ACT). Additionally, we assessed emerging research on biomarkers predictive responsiveness Results: The findings indicate that immunotherapy, particularly involving inhibitors other demonstrates some showing enhanced benefits specific subtypes. microenvironment platinum-sensitive -resistant cases exhibits distinct immunological profiles, influencing therapy outcomes. Several been identified, potentially aiding patient stratification treatment optimization. Conclusions: significantly treatment, improving Further characteristics is crucial personalizing approaches enhancing their managing
Language: Английский
Citations
0
Pathogens, Journal Year: 2025, Volume and Issue: 14(2), P. 140 - 140
Published: Feb. 3, 2025
Ovarian cancer (OC) remains the most lethal gynecologic malignancy with limited effective treatment options. Oncolytic viruses (OVs) have emerged as a promising therapeutic approach for treatment, capable of selectively infecting and lysing cells while stimulating anti-tumor immune responses. Preclinical studies demonstrated significant tumor regression prolonged survival in OC models using various OVs, such herpes simplex. Early-phase clinical trials shown favorable safety profile, though impact on patient has been modest. Current research focuses combining OVs other treatments like checkpoint inhibitors to enhance their efficacy. We provide comprehensive overview current understanding future directions utilizing management OC.
Language: Английский
Citations
0
European Journal of Pharmaceutical Sciences, Journal Year: 2025, Volume and Issue: unknown, P. 107032 - 107032
Published: Feb. 1, 2025
Language: Английский
Citations
0
BMJ Open, Journal Year: 2025, Volume and Issue: 15(2), P. e092545 - e092545
Published: Feb. 1, 2025
Introduction The prognosis for epithelial ovarian cancer (EOC) is exceedingly poor, with patients diagnosed stage III/IV tumours typically offered cytoreductive surgery in conjunction chemotherapy as a standard treatment option. This approach intended to reduce the risk of and address cancers that are not amenable surgical intervention. A promising alternative important option neoadjuvant (NACT) interstitial tumour surgery. combination immunotherapy has recently demonstrated remarkable efficacy, particularly melanoma lung cancer, notable pathological responses therapeutic benefits tissue. NeoAdjuvant or without tIslelizumab followed by debulking oVarian cancEr(NAIVE) study aims assess clinical efficacy safety NACT tislelizumab (a monoclonal antibody programmed cell death protein 1) advanced EOC. Methods analysis NAIVE an investigator-initiated, prospective, single-centre, open-label, randomised controlled trial EOC International Federation Gynaecology Obstetrics (FIGO) IIIc Suidan CT score 3 greater Fagotti laparoscopic 8 greater; FIGO IV. primary endpoint 1-year progression-free survival (PFS) rate, measured percentage who free progression 1 year after receiving first dose drug. secondary endpoints encompassed R0 resection response rate other relevant metrics. Enrolled will be randomly assigned 1:1 ratio either experimental arm, which receive platinum-based tislelizumab, control chemotherapy. enrol 40 patients, enrolment scheduled start April 2021 complete 2025, given PFS 60%. provide new evidence regarding cancer. results contribute deeper understanding effects, profile fundamental immunological processes. findings growing body support incorporation into paradigm thus facilitating development more personalised efficacious modalities. Ethics dissemination received ethical approval from Institutional Committee Second Affiliated Hospital Medical College Zhejiang University. Presentations at scientific professional meetings publication peer-reviewed journals disseminate study. Trial registration number NCT04815408 .
Language: Английский
Citations
0
Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16
Published: Feb. 6, 2025
Epithelial ovarian cancer (EOC) is a that affects the female reproductive system and highly lethal. It poses significant challenges in terms of treatment often has poor prognosis. In recent years, with advent PARPi, entered new stage full-process management. Although more drugs have been approved, therapeutic effect PARPi still very limited. With rapid development PD-1/PD-L1, CTLA-4, oncolytic viruses, vaccines, adoptive cell therapy, etc., tumor immunotherapy provided opportunities for cancer. This study used comprehensive transcriptome analysis across multiple databases to gather gene transcripts clinical features normal samples tissue from The aim was explore mechanisms underlying resistance reveal relationship between cancer's immune microenvironment genes linked inflammation. Various R packages were differential analysis, enrichment co-expression network construction, prognostic model building. found prognosis patients closely associated sets involved infiltration microenvironment, clinicopathological features, survival rates differed significantly two inflammatory expression patterns identified using cluster analyses. Further revealed high-risk group had higher abundance M2-type macrophage infiltration, active anti-tumor response, stemness score, potentially worse prognosis, lower response chemotherapy checkpoint inhibitors. These findings provide perspectives potential targets evaluation offer strategies directions patient provides crucial information further our comprehension drug immunotherapy. offers methods improvement
Language: Английский
Citations
0
Advanced Science, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 7, 2025
A major characteristic of ovarian cancer (OC) is its unique route metastasis via ascites. The immune microenvironment in ascites remains understudied, leaving the mechanism ascites-mediated abdominal obscure. Here, a single-cell transcriptomic landscape CD45+ cells across multiple anatomical sites depicted, including primary tumors, metastatic lesions, and ascites, from patients diagnosed with high-grade serous carcinoma (HGSOC). novel subset perilipin 2 high (PLIN2hi) macrophages are identified that enriched positively correlated OC progression, hence being designated as "ascites-associated (AAMs)". AAMs lipid-loaded overexpression lipid droplet protein PLIN2. Overexpression or suppression PLIN2 can enhance inhibit tumor cell migration, invasion, vascular permeability vitro, which also confirmed vivo. Mechanistically, it demonstrated boosts HIF1α/SPP1 signaling macrophages, thereby exerting pro-tumor functions. Finally, PLIN2-targeting liposome designed to efficiently suppress production metastasis. Taken together, this work provides comprehensive characterization cancer-promoting function lipid-rich property ascites-enriched PLIN2hi establishes link between metabolism hypoxia within context microenvironment, elucidates pivotal role trans-coelomic OC.
Language: Английский
Citations
0
Clinical and Translational Medicine, Journal Year: 2025, Volume and Issue: 15(2)
Published: Feb. 1, 2025
Language: Английский
Citations
0